1,020 filings
6-K
ONCY
Oncolytics Biotech, Inc.
12 Apr 24
Notice of Annual General Meeting
11:03am
6-K
ONCY
Oncolytics Biotech, Inc.
11 Apr 24
Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA
10:03am
6-K
ONCY
Oncolytics Biotech, Inc.
2 Apr 24
Oncolytics Biotech® to Participate in a Panel Presentation at Canaccord Genuity’s Horizons in Oncology Virtual Conference
8:02am
20-F
2023 FY
ONCY
Oncolytics Biotech, Inc.
Annual report (foreign)
12 Mar 24
4:10pm
6-K
ONCY
Oncolytics Biotech, Inc.
7 Mar 24
Oncolytics Biotech® Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
4:06pm
6-K
piyx2bjhd 8f
5 Mar 24
Oncolytics Biotech® Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN
1:08pm
6-K
aspsnik0b3 sgww
4 Mar 24
Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights
12:37pm
6-K
xr3pvb2v9edlzc1
28 Feb 24
Oncolytics Biotech® Announces Presentation at the Cancer Advocacy Group of Louisiana’s 3rd Annual NeauxCancer Conference
1:09pm
6-K
6in5ao9u2fd x7eib29
14 Feb 24
Current report (foreign)
8:30am
6-K
b5s7258q7wv7fxc98rce
9 Jan 24
Oncolytics Biotech® Appoints Patricia S. Andrews to its Board of Directors
8:44am
6-K
tbv4hfo
4 Jan 24
Oncolytics Biotech® Recaps 2023 Accomplishments, Provides Outlook for 2024
1:01pm
6-K
awhelbv8
7 Dec 23
Oncolytics Biotech® and SOLTI Present Positive Translational Data at SABCS
10:37am
6-K
wnj zjdpvh6olmq8u
9 Nov 23
Oncolytics Announces the Anal Cancer Cohort of the GOBLET Phase 1/2 Study of Pelareorep and Atezolizumab Has Met the Success Criteria for Efficacy
1:21pm
6-K
ric2fbtez7 0q7p1kq3
9 Nov 23
Oncolytics Provides Update on Pancreatic Cancer Program for Pelareorep
1:00pm
6-K
ddll06zwg8ms7rh
3 Nov 23
Oncolytics Biotech® and SOLTI Present Further Positive Pelareorep Translational Data at SITC
2:01pm
6-K
9xxc2fhm421u0c
3 Nov 23
Condensed Interim Consolidated Financial Statements
11:18am
6-K
urljpsg30cckt9vsw
3 Nov 23
Oncolytics Biotech® Reports Third Quarter 2023 Financial Results and Operational Highlights
11:17am
6-K
mffi6jfa92jdx c8
23 Oct 23
Oncolytics Presents Positive Updated Pancreatic Cancer Data from GOBLET Phase 1/2 Study at ESMO
12:33pm
6-K
u2csxu4rq4fexj2tahx
23 Oct 23
Oncolytics Achieves Success Criteria for Efficacy in the Third-Line Colorectal Cancer Cohort of the GOBLET Study
12:26pm
6-K
n5proaow
20 Oct 23
Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights
3:07pm